Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder

Pharmacological Reviews(2020)10.1124/pr.119.018028Source: DataRank Database

More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder is a research paper published in Pharmacological Reviews (2020). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

Linked data & code

gen doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.67)OA: bronzeTopics (35)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Lance R. McMahon ORCID,Jenny L. Wilkerson ORCID,Megan J. Moerke ORCID

Live enrichment

PubMed:32205338 PMC:PMC7090325 OpenAlex:https://openalex.org/W3012808042

NIDA NIH HHS

Grant: R01 DA025267

NIDA NIH HHS

Grant: UG3 DA048353

National Institutes of Health

Grant: 1UG3DA048353-01

Opioid use disorders: UF Pharmacy medications discovery and development

National Institutes of Health

Grant: 5R01DA025267-09

Nicotine dependence: neuropharmacology in monkeys

FWCI

0.67

Citation Percentile

0.7%

Citation Trend

2020

2021

2023

2024

bronzeLicense: Elsevier TDM

journalhttps://pharmrev.aspetjournals.org/content/pharmrev/72/2/527.full.pdf

publisherhttps://pharmrev.aspetjournals.org/content/pharmrev/72/2/527.full.pdf

publisherhttps://api.elsevier.com/content/article/PII:S003169972400958X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S003169972400958X?httpAccept=text/plain

publisherhttps://syndication.highwire.org/content/doi/10.1124/pr.119.018028

Fields of Study

Nicotinic Acetylcholine Receptors StudySmoking Behavior and CessationNeurotransmitter Receptor Influence on Behavior0301 basic medicine03 medical and health sciences0302 clinical medicineAnimalsClinical Trials, Phase III as TopicHumansNicotineNicotinic AntagonistsReceptors, NicotinicSmoking CessationTobacco Use Disorder

MeSH Terms

AnimalsHumansNicotineReceptors, NicotinicTobacco Use DisorderSmoking CessationClinical Trials, Phase III as TopicNicotinic Antagonists

Keywords

MedicineTobacco smokeNicotineTobacco usePsychiatryEnvironmental healthClinical Trials, Phase III as TopicAnimalsHumansSmoking CessationNicotinic AntagonistsTobacco Use DisorderReceptors, Nicotinic

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being